Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Chemotherapy in Neoadjuvant Resectable NSCLC (TD-FOREKNOW)
NCT04338620Phase 2
Key facts
- Status
- Unknown
- Start
- Apr 2020
- Primary completion
- Nov 2023
- Countries
- 1
- Sponsor
- Tangdu Hospital
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- camrelizumab
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: pathological complete response. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Experimental Group
Camrelizumab + nab-paclitaxel + platinum
Control Group
nab-paclitaxel + platinum
03
Who it enrols
Adult patients (18-70 years) with resectable stage IIIA-IIIB (T3N2) NSCLC, ECOG 0-1, and no prior systemic treatment.
04
Endpoints
Primary
pathological complete response
Secondary
major pathology rate
Objective Response Rate
Event-free Survival
Adverse Events
Beyond the preview
Go deeper on NCT04338620.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338620.